|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
AstraZeneca |
Pozen |
$375M licensing deal |
The companies will co-develop remedies for chronic pain utilizing Pozen's technology. Pozen gets $40 million up front and up to $335 million in additional milestone payments. |
|
Amgen |
Predix |
$307M licensing deal |
Amgen will pay an initial $20 million for Predix's autoimmune disease treatment and up to an additional $287.5 million in milestone payments. |
|
Nextar |
Affymax |
$17.6M licensing agreement |
Nektar is providing Affymax with technology to develop Hematide. The deal was previously undisclosed. |
|
YM BioSciences |
Daiichi Pharmaceutical |
$14.5M licensing deal |
YM BioSciences has licensed developing and marketing rights for nimotuzumab for an up-front payment of $14.5 million plus additional milestone payments. |
|
Archemix |
Nuvelo |
collaboration |
Archemix and Nuvelo have expanded their collaboration. Archemix will be responsible for research and Nuvelo will be responsible for development and commercialization. |
|
Enzon |
Santaris |
collaboration |
Enzon will develop and commercialize a series of RNA antagonists based on Santaris technology. |
|
Avalon |
ChemDiv |
collaboration |
The companies are collaborating for the discovery and development of small molecule oncology therapeutics. |
|
Eli Lilly |
Alcon |
collaboration |
The companies signed a long-term agreement to co-promote ruboxistaurin mesylat. |
|
Biovail |
Athpharma |
partnership |
The companies are ending their development partnership for four cardiovascular drugs. |
|
Dainippon Sumitomo |
Bristol-Myers K.K. |
partnership |
Bristol-Myers will license to Dainippon the development rights of irbesartan. Dainippon will grant Bristol-Myers with co-marketing rights of miriplatin hydrate. |
|
Receptor BioLogix |
Aphton |
acquisition |
Receptor BioLogix has acquired the cancer vaccine Insegia and related assets from Aphton in a Chapter 11 sale. |
|
Cambridge Antibody Technology |
Enzon |
acquisition |
Cambridge acquired the license to CAT-5001 from Enzon. |
|
Iconix |
Merck KGaA |
services agreement |
Iconix will compare several of Merck's compounds to similar products to gain insight into the safety of new drug candidates in the early stages of pre-clinical development. |